Clinical Trial

A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes

Study acronym: TELOS
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-07.
Status change: Not Yet Recruiting → Recruiting 2025-09-11
Trial Details
NCT Number NCT06972732
Lead Sponsor Boryung Pharmaceutical Co., Ltd
Conditions Type 2 Diabetes
Enrollment 204 participants
Start Date 2025-06-11
Primary Completion 2026-10-01 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-15